Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health

Véronique Raimond (), Emmanuelle Kaltenbach, Christophe Adam, Sébastien Lazzarotto, Catherine Le Galès, Lionel Perrier and Jérôme Wittwer
Additional contact information
Véronique Raimond: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]
Emmanuelle Kaltenbach: HAS - Haute Autorité de Santé [Saint-Denis La Plaine]

Post-Print from HAL

Date: 2021-10
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in Bulletin du Cancer, 2021, ⟨10.1016/j.bulcan.2021.09.001⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-03428067

DOI: 10.1016/j.bulcan.2021.09.001

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().